德谷門冬雙胰島素是由新一代超長效基礎(chǔ)胰島素類似物（德谷胰島素）聯(lián)合餐時胰島素類似物（門冬胰島素）組成的新型胰島素類似物復(fù)方制劑，可以每天使用一或兩次，同時提供基礎(chǔ)和餐時胰島素需求，與目前的胰島素制劑相比具有較低的低血糖風(fēng)險。綜述了德谷門冬雙胰島素與預(yù)混胰島素、基礎(chǔ)餐時胰島素及基礎(chǔ)胰島素方案比較的臨床研究進展，為臨床上更好地應(yīng)用提供參考。

Insulin degludec/insulin aspart is a compound preparation of new type insulin consisting of a ultra-long acting basal insulin (Degludec) and a bolus insulin (Aspart).It can be used once or twice-daily,providing reliable coverage of both basal and prandial insulin requirements with a lower risk of hypoglycaemia than current insulin options.This article reviews clinical trials on comparing IDegAsp with three other currently available treatment options:premixed insulin,basal-bolus regimens and basal-only therapy,with view to providing references in clinical application.